Compare Divis Laboratories with AJANTA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DIVIS LABORATORIES vs AJANTA PHARMA - Comparison Results

DIVIS LABORATORIES     Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DIVIS LABORATORIES AJANTA PHARMA DIVIS LABORATORIES/
AJANTA PHARMA
 
P/E (TTM) x 60.0 24.3 246.7% View Chart
P/BV x 13.8 6.0 230.1% View Chart
Dividend Yield % 0.4 0.6 75.3%  

Financials

 DIVIS LABORATORIES   AJANTA PHARMA
EQUITY SHARE DATA
    DIVIS LABORATORIES
Mar-19
AJANTA PHARMA
Mar-19
DIVIS LABORATORIES/
AJANTA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,6391,422 115.3%   
Low Rs1,115898 124.2%   
Sales per share (Unadj.) Rs186.3233.5 79.8%  
Earnings per share (Unadj.) Rs51.044.0 115.9%  
Cash flow per share (Unadj.) Rs57.352.2 109.9%  
Dividends per share (Unadj.) Rs16.009.00 177.8%  
Dividend yield (eoy) %1.20.8 149.7%  
Book value per share (Unadj.) Rs261.8255.1 102.6%  
Shares outstanding (eoy) m265.4788.02 301.6%   
Bonus/Rights/Conversions -BB-  
Price / Sales ratio x7.45.0 148.8%   
Avg P/E ratio x27.026.4 102.5%  
P/CF ratio (eoy) x24.022.2 108.0%  
Price / Book Value ratio x5.34.5 115.7%  
Dividend payout %31.420.5 153.4%   
Avg Mkt Cap Rs m365,592102,081 358.1%   
No. of employees `00011.86.8 174.2%   
Total wages/salary Rs m5,4234,307 125.9%   
Avg. sales/employee Rs Th4,175.13,022.6 138.1%   
Avg. wages/employee Rs Th457.7633.4 72.3%   
Avg. net profit/employee Rs Th1,141.8569.1 200.6%   
INCOME DATA
Net Sales Rs m49,46320,554 240.7%  
Other income Rs m1,556211 738.3%   
Total revenues Rs m51,01920,765 245.7%   
Gross profit Rs m18,7185,664 330.5%  
Depreciation Rs m1,689721 234.3%   
Interest Rs m3512 301.7%   
Profit before tax Rs m18,5515,143 360.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,0231,273 394.6%   
Profit after tax Rs m13,5273,870 349.6%  
Gross profit margin %37.827.6 137.3%  
Effective tax rate %27.124.8 109.4%   
Net profit margin %27.318.8 145.3%  
BALANCE SHEET DATA
Current assets Rs m46,50111,812 393.7%   
Current liabilities Rs m8,4683,776 224.2%   
Net working cap to sales %76.939.1 196.7%  
Current ratio x5.53.1 175.6%  
Inventory Days Days13177 169.0%  
Debtors Days Days8682 105.2%  
Net fixed assets Rs m25,79714,398 179.2%   
Share capital Rs m531175 302.7%   
"Free" reserves Rs m68,96222,277 309.6%   
Net worth Rs m69,49322,452 309.5%   
Long term debt Rs m07 0.0%   
Total assets Rs m80,38326,962 298.1%  
Interest coverage x531.0444.3 119.5%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.60.8 80.7%   
Return on assets %16.914.4 117.2%  
Return on equity %19.517.2 112.9%  
Return on capital %26.723.0 116.5%  
Exports to sales %00-   
Imports to sales %24.60-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m12,187NA-   
Fx inflow Rs m41,23810,682 386.1%   
Fx outflow Rs m12,4052,102 590.2%   
Net fx Rs m28,8338,580 336.1%   
CASH FLOW
From Operations Rs m9,5433,748 254.6%  
From Investments Rs m-6,854-2,228 307.6%  
From Financial Activity Rs m-2,459-1,475 166.8%  
Net Cashflow Rs m23045 508.0%  

Share Holding

Indian Promoters % 52.0 73.8 70.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 11.8 1.6 761.3%  
FIIs % 19.0 7.6 250.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.2 17.0 101.2%  
Shareholders   31,796 20,968 151.6%  
Pledged promoter(s) holding % 0.0 4.4 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DIVIS LABORATORIES With:   SANOFI INDIA  TORRENT PHARMA  FRESENIUS KABI ONCO.  CIPLA  ABBOTT INDIA  

Compare DIVIS LABORATORIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Higher; Dow Futures Up by 232 Points(12:30 pm)

Share markets in India are presently trading on a strong note. The BSE Sensex is trading up by 389 points, up 0.9% at 44,539 levels.

Related Views on News

PROCTER & GAMBLE HEALTH at All Time High; BSE HEALTHCARE Index Up 1.4% (Market Updates)

Dec 1, 2020 | Updated on Dec 1, 2020

PROCTER & GAMBLE HEALTH share price has hit an all time high at Rs 7,025 (up 1.5%). The BSE HEALTHCARE Index is up by 1.4%. Among the top gainers in the BSE HEALTHCARE Index today are PROCTER & GAMBLE HEALTH (up 1.5%) and ABBOTT INDIA . The top losers include NARAYANA HRUDAYALAYA (down 0.1%) and GSK PHARMA (down 0.3%).

DIVIS LABORATORIES at All Time High; BSE HEALTHCARE Index Up 1.0% (Market Updates)

Dec 1, 2020 | Updated on Dec 1, 2020

DIVIS LABORATORIES share price has hit an all time high at Rs 3,760 (up 2.3%). The BSE HEALTHCARE Index is up by 1.0%. Among the top gainers in the BSE HEALTHCARE Index today are DIVIS LABORATORIES (up 2.3%) and ABBOTT INDIA . The top losers include DR. LAL PATHLABS (down 0.1%) and JUBILANT LIFE SCIENCES (down 0.4%).

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

Not Infosys or Wipro. India's Next Wealth Creators Could Be Drone Stocks(Profit Hunter)

Nov 25, 2020

India's drones directorate signals the next big defence tech multibaggers.

It's Time to Book Profits(Fast Profits Daily)

Nov 27, 2020

In my first video on Equitymaster, I want to introduce you my proprietary greed and fear index. It's telling us to book some profits in the market.

How the New Margins Will Impact You(Fast Profits Daily)

Nov 25, 2020

The new rules on margins will come into effect from 1st December. Are you ready?

Is this Sector the Best Contrarian Bet Right Now?(Profit Hunter)

Nov 23, 2020

The risk reward ratio in this beaten down sector may have finally turned for the better.

The Price of Dying, the Cost of Living(The Honest Truth)

Nov 20, 2020

Ajit Dayal presents a cost benefit analysis of the various types of response to covid around the world.

More

Covid-19 Proof
Multibagger Stocks

Covid19 Proof Multibaggers
Get this special report, authored by Equitymaster's top analysts now!
We will never sell or rent your email id.
Please read our Terms

DIVIS LABORATORIES SHARE PRICE


Dec 1, 2020 02:52 PM

TRACK DIVIS LABORATORIES

  • Track your investment in DIVIS LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON DIVIS LABORATORIES

DIVIS LABORATORIES 8-QTR ANALYSIS

COMPARE DIVIS LABORATORIES WITH

MARKET STATS